問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Hsinchu Mackay Memorial Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 300Hsinchu CityHsinchu East

Recruiting Trial

18Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

49Cases

2020-06-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2021-09-01 - 2027-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-01-01 - 2025-12-31

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2020-03-17 - 2024-05-02

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2021-04-09 - 2024-12-31

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2021-06-21 - 2022-06-30

Phase II

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Terminated5Sites

2014-12-01 - 2017-03-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan

  • Condition/Disease

    High Cardiovascular Risk Patients With Hypercholesterolemia

  • Test Drug

    Alirocumab

Participate Sites
13Sites

Terminated13Sites

2013-02-15 - 2018-09-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome

  • Condition/Disease

    Acute Coronary Syndrome

  • Test Drug

    SAR236553/REGN727

Participate Sites
15Sites

Terminated15Sites

蔡惟全
National Taiwan University Hospital

Division of Cardiovascular Diseases

2015-09-01 - 2018-11-30

Phase III

Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss (HEALOS)

  • Condition/Disease

    Acute Inner Ear Hearing Loss

  • Test Drug

    AM-111

Participate Sites
9Sites

Terminated9Sites

2018-11-01 - 2021-01-31

Phase II

A Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 Days and <=3 Years of Age With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus(RSV) Infection

  • Test Drug

    JNJ-53718678/Placebo

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB